



Press release from Emotra AB (publ)

Göteborg, February 6, 2020

## **Emotra signs an agreement with a hospital to study depression relapse**

**The Company is now taking an important first step for the new indication area for EDOR® Test – depression relapse. The psychiatric clinic at the Warsaw University Hospital has signed a research collaboration agreement to mainly study the connection between hyporeactivity and depression relapse.**

In 2019, the Company received data from a study conducted by researchers at a psychiatric hospital. Their study showed that depressed patients who were identified as hyporeactive using the EDOR® Test run a significantly higher risk of depression relapse compared to normally reactive patients. Lately, we have been negotiating with researchers and clinics about the possibility of conducting studies with the goal of verifying these first study results.

The company aims to compile a portfolio of results from various clinical centres of, among other things, depression relapse in different clinical situations. We are in discussions with various research groups for further studies with the goal of providing more data that underscore hyporeactivity as a biomarker for mental illness. At present, the psychiatric profession does not have an objective method for identifying patients that risk depression relapse.

Access to biomarkers that can help identify a risk of relapse is considered by today's psychiatrists to be one of their most urgent needs. It is estimated that half of all patients who recover from their first depression will suffer one or two more episodes in their lives, and that 80 percent of patients who have experienced two episodes will suffer a new relapse. This affects a large number of patients and the cost to society is very high.

In Sweden alone, the cost of psychiatric disorders is estimated to be about 75 billion SEK per year, with depression accounting for the lion's share of this, about 35 billion SEK. These high yearly costs are due to absence from work due to illness and lost productivity, but are also largely due to the fact that depressions are recurrent. This is an area in which early diagnostics could contribute valuable biological information that would enable individualised care planning with the goal of preventing future relapses.

In this context, it is important to point out that reducing the rate of depression relapse also leads to reduced risk of suicide and suicide attempts.

**For further information about Emotra, please contact:**

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: [daniel@emotra.se](mailto:daniel@emotra.se)

*This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on February 6, 2020, under the above contact's supervision.*

---

**Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.